Fresh millions for Danish biotech company
A Danish biotech company has raised millions through a capital increase. The money will go towards bringing one of the company’s cancer drugs to phase II. The company is also in talks with potential partners concerning another cancer drug.
by Stefan Singh Kailay
The biotech company Cytovac has raised 10.5 million kroner (USD 1.9 million) through a capital increase from private investors.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
